MiR-3613-3p from carcinoma-associated fibroblasts exosomes promoted breast cancer cell proliferation and metastasis by regulating SOCS2 expression.


Journal

IUBMB life
ISSN: 1521-6551
Titre abrégé: IUBMB Life
Pays: England
ID NLM: 100888706

Informations de publication

Date de publication:
08 2020
Historique:
received: 20 03 2020
accepted: 07 04 2020
pubmed: 29 4 2020
medline: 24 11 2021
entrez: 29 4 2020
Statut: ppublish

Résumé

Exosomes carrying microRNAs (miRNAs) mediate cell-to-cell communication, which play important roles in cancer growth and progression. However, the roles and molecular mechanisms of the miRNAs in the exosomes from carcinoma-associated fibroblasts (CAFs) are still not clear. The miRNA array showed that miR-3613-3p was an upregulated miRNA in CAFs exosomes. It was verified that miR-3613-3p was upregulated in exosomes from fibroblasts educated by TGF-β1 and the fibroblasts from breast cancer tissues. Exosomal miR-3613-3p promoted breast cancer cell proliferation and metastasis. The cellular functions showed that miR-3613-3p downregulation in the CAFs exosomes suppressed cell proliferation and metastasis in breast cancer by targeting SOCS2 expression. The clinical data showed that miR-3613-3p levels were negatively related to SOCS2 expression in breast cancer tissues. In a conclusion, the study demonstrated that activated fibroblasts exosomes with high levels of miR-3613-3p played an oncogenic role in breast cancer cell survival and metastasis, which suggested that miR-3613-3p function as a therapeutic target.

Identifiants

pubmed: 32344463
doi: 10.1002/iub.2292
doi:

Substances chimiques

MIRN3613 microRNA, human 0
MicroRNAs 0
SOCS2 protein, human 0
Suppressor of Cytokine Signaling Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1705-1714

Informations de copyright

© 2020 International Union of Biochemistry and Molecular Biology.

Références

Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18:84.
Cheng HS, Lee JXT, Wahli W, Tan NS. Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment. Mol Cancer. 2019;18:51.
Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. Genes Dev. 2016;30:1002-1019.
Santi A, Kugeratski FG, Zanivan S. Cancer associated fibroblasts: The architects of stroma remodeling. Proteomics. 2018;18:e1700167.
Prakash J. Cancer-associated fibroblasts: Perspectives in cancer therapy. Trends Cancer. 2016;2:277-279.
Whiteside TL. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. Semin Immunol. 2018;35:69-79.
Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18:70.
Yang F, Ning Z, Ma L, et al. Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts. Mol Cancer. 2017;16(1):148.
Wortzel I, Dror S, Kenific CM, Lyden D. Exosome-mediated metastasis: Communication from a distance. Dev Cell. 2019;49:347-360.
Wang X, Qin X, Yan M, et al. Loss of exosomal miR-3188 in cancer-associated fibroblasts contributes to HNC progression. J Exp Clin Cancer Res. 2019;38(1):151.
Xu G, Zhang B, Ye J, et al. Exosomal miRNA-139 in cancer-associated fibroblasts inhibits gastric cancer progression by repressing MMP11 expression. Int J Biol Sci. 2019;15(11):2320-2329.
Qin X, Guo H, Wang X, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019;20(1):12.
Li YY, Tao YW, Gao S, et al. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p. EBioMedicine. 2018;36:209-220.
Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11:37-51.
Fang T, Lv H, Lv G, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. 2018;9(1):191.
Ghafouri-Fard S, Oskooei VK, Azari I, Taheri M. Suppressor of cytokine signaling (SOCS) genes are downregulated in breast cancer. World J Surg Oncol. 2018;16(1):226.
Sutherland KD, Lindeman GJ, Choong DY, et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene. 2004;23(46):7726-7733.
Leung KC, Brce J, Doyle N, et al. Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases. Endocrinology. 2007;148(5):2417-2423.
Farabegoli F, Ceccarelli C, Santini D, Taffurelli M. Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol. 2005;58(10):1046-1050.
Das R, Gregory PA, Fernandes RC, et al. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Res. 2017;77(4):1021-1034.
Ren W, Wu S, Wu Y, Liu T, Zhao X, Li Y. MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2. Cell Death Dis. 2019;10(5):333.
Jiang C, Long J, Liu B, et al. miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2017;36(1):99.
Nagpal N, Ahmad HM, Molparia B, Kulshreshtha R. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. Carcinogenesis. 2013;34(8):1889-1899.
He J, Jiang BH. Interplay between reactive oxygen species and MicroRNAs in cancer. Curr Pharmacol Rep. 2016;2(2):82-90.
Gurer-Orhan H, Ince E, Konyar D, Saso L, Suzen S. The role of oxidative stress modulators in breast cancer. Curr Med Chem. 2018;25(33):4084-4101.

Auteurs

Yonglei Liu (Y)

Research Center, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.

Yanfei Yang (Y)

Research Center, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.

Junxian Du (J)

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Dong Lin (D)

Research Center, Zhongshan Hospital, Fudan University, Shanghai, China.

Feng Li (F)

Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH